Logo image of ETNB

89BIO INC (ETNB) Stock Overview

USA - NASDAQ:ETNB - US2825591033 - Common Stock

14.79 USD
-0.01 (-0.07%)
Last: 10/24/2025, 8:21:32 PM
14.78 USD
-0.01 (-0.07%)
After Hours: 10/24/2025, 8:21:32 PM

ETNB Key Statistics, Chart & Performance

Key Statistics
Market Cap2.20B
Revenue(TTM)N/A
Net Income(TTM)-450206000
Shares148.49M
Float147.65M
52 Week High15.06
52 Week Low4.16
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.61
PEN/A
Fwd PEN/A
Earnings (Next)11-06 2025-11-06/amc
IPO2019-11-11
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ETNB short term performance overview.The bars show the price performance of ETNB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

ETNB long term performance overview.The bars show the price performance of ETNB in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80

The current stock price of ETNB is 14.79 USD. In the past month the price increased by 0.61%. In the past year, price increased by 87.93%.

89BIO INC / ETNB Daily stock chart

ETNB Latest News, Press Relases and Analysis

ETNB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.53 402.76B
AMGN AMGEN INC 13.38 157.07B
GILD GILEAD SCIENCES INC 15.63 150.06B
VRTX VERTEX PHARMACEUTICALS INC 24.88 108.04B
REGN REGENERON PHARMACEUTICALS 12.66 61.26B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.75B
ARGX ARGENX SE - ADR 88.74 50.32B
ONC BEONE MEDICINES LTD-ADR 5.02 34.14B
INSM INSMED INC N/A 33.75B
NTRA NATERA INC N/A 26.42B
BNTX BIONTECH SE-ADR N/A 25.40B
BIIB BIOGEN INC 9.36 21.98B

About ETNB

Company Profile

ETNB logo image 89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.

Company Info

89BIO INC

655 Montgomery Street, Suite 1500

San Francisco CALIFORNIA 94104 US

CEO: Rohan Palekar

Employees: 93

ETNB Company Website

ETNB Investor Relations

Phone: 14154329270

89BIO INC / ETNB FAQ

What does 89BIO INC do?

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company is headquartered in San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2019-11-11. The firm is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.


What is the current price of ETNB stock?

The current stock price of ETNB is 14.79 USD. The price decreased by -0.07% in the last trading session.


What is the dividend status of 89BIO INC?

ETNB does not pay a dividend.


How is the ChartMill rating for 89BIO INC?

ETNB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is 89BIO INC worth?

89BIO INC (ETNB) has a market capitalization of 2.20B USD. This makes ETNB a Mid Cap stock.


When does 89BIO INC (ETNB) report earnings?

89BIO INC (ETNB) will report earnings on 2025-11-06, after the market close.


Can you provide the ownership details for ETNB stock?

You can find the ownership structure of 89BIO INC (ETNB) on the Ownership tab.


ETNB Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ETNB. When comparing the yearly performance of all stocks, ETNB is one of the better performing stocks in the market, outperforming 94.3% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ETNB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ETNB. While ETNB seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ETNB Financial Highlights

Over the last trailing twelve months ETNB reported a non-GAAP Earnings per Share(EPS) of -3.61. The EPS decreased by -83.25% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -74.6%
ROE -86.29%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%-47.92%
Sales Q2Q%N/A
EPS 1Y (TTM)-83.25%
Revenue 1Y (TTM)N/A

ETNB Forecast & Estimates

14 analysts have analysed ETNB and the average price target is 29.52 USD. This implies a price increase of 99.57% is expected in the next year compared to the current price of 14.79.


Analysts
Analysts77.14
Price Target29.52 (99.59%)
EPS Next Y34.48%
Revenue Next YearN/A

ETNB Ownership

Ownership
Inst Owners110.73%
Ins Owners0.55%
Short Float %5.9%
Short Ratio1.71